ANA Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ANA Therapeutics, Inc. - overview
Established
2020
Location
Foster City, CA, US
Primary Industry
Biotechnology
About
ANA Therapeutics, Inc. is a biotechnology company dedicated to developing innovative therapies that enhance patient outcomes through advanced technology and research in the pharmaceutical sector. Founded in 2020 and headquartered in Foster City, US, ANA Therapeutics focuses on the development of novel therapeutic solutions. In January 2021, NeuroBo Pharmaceuticals, Inc.
acquired full ownership of ANA Therapeutics, although the financial terms of the acquisition were not disclosed. The company has secured a total of USD 5. 00 mn through its SEED funding round, with investors such as Refactor Capital, SOSV, SV Angel, and SV Tech Ventures contributing. The most recent funding round occurred on January 6, 2021, marking a total of three deals to date.
ANA Therapeutics specializes in developing technology-driven therapeutic solutions aimed at enhancing operational efficiency within the healthcare sector. Their current offerings focus on innovative drug development processes integrating advanced research methodologies and clinical solutions, primarily targeting health professionals and organizations involved in patient care. These products aim to optimize treatment efficacy and patient management strategies, serving diverse healthcare needs across various markets. ANA Therapeutics operates under a revenue model based on securing funding through investment rounds, specifically focusing on partnerships and collaborations in the biotech arena.
The funding secured facilitates ongoing research and development initiatives, creating a foundation for future revenue generation through potential therapeutic offerings in the market. With the recent funding, ANA Therapeutics plans to enhance its research and development capabilities, aiming to launch new therapeutic products tailored for specific health conditions by the end of 2023. The company is focused on expanding its market presence, targeting geographical regions including North America and Europe for additional partnerships and collaborations. This expansion will leverage the recent investment to advance clinical trials and product launches, positioning the company for significant growth in the biotech sector.
Current Investors
NeuroBo Pharmaceuticals, Inc.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.anatherapeutics.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
ANA Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.